HRP20110643T1 - Mjesto vezanja visokog afiniteta za receptor faktora rasta hepatocita (hgfr) i postupci za identifikaciju njegovih antagonista - Google Patents

Mjesto vezanja visokog afiniteta za receptor faktora rasta hepatocita (hgfr) i postupci za identifikaciju njegovih antagonista Download PDF

Info

Publication number
HRP20110643T1
HRP20110643T1 HR20110643T HRP20110643T HRP20110643T1 HR P20110643 T1 HRP20110643 T1 HR P20110643T1 HR 20110643 T HR20110643 T HR 20110643T HR P20110643 T HRP20110643 T HR P20110643T HR P20110643 T1 HRP20110643 T1 HR P20110643T1
Authority
HR
Croatia
Prior art keywords
growth factor
factor receptor
hepatocyte growth
ipt
cancer
Prior art date
Application number
HR20110643T
Other languages
English (en)
Croatian (hr)
Inventor
Maria Comoglio Paolo
Carminati Paolo
Michieli Paolo
Basilico Cristina
Original Assignee
Metheresis Translational Research Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metheresis Translational Research Sa filed Critical Metheresis Translational Research Sa
Publication of HRP20110643T1 publication Critical patent/HRP20110643T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20110643T 2008-05-14 2011-09-07 Mjesto vezanja visokog afiniteta za receptor faktora rasta hepatocita (hgfr) i postupci za identifikaciju njegovih antagonista HRP20110643T1 (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08103958 2008-05-14

Publications (1)

Publication Number Publication Date
HRP20110643T1 true HRP20110643T1 (hr) 2011-10-31

Family

ID=40984839

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110643T HRP20110643T1 (hr) 2008-05-14 2011-09-07 Mjesto vezanja visokog afiniteta za receptor faktora rasta hepatocita (hgfr) i postupci za identifikaciju njegovih antagonista

Country Status (18)

Country Link
US (4) US8404453B2 (de)
EP (1) EP2119448B1 (de)
JP (1) JP5623027B2 (de)
KR (1) KR101509263B1 (de)
AT (1) ATE513556T1 (de)
BR (1) BRPI0901502A2 (de)
CA (1) CA2665958C (de)
CY (1) CY1111853T1 (de)
DK (1) DK2119448T3 (de)
EA (1) EA017863B1 (de)
ES (1) ES2368603T3 (de)
HR (1) HRP20110643T1 (de)
IL (1) IL198545A0 (de)
MX (1) MX2009005049A (de)
PL (1) PL2119448T3 (de)
PT (1) PT2119448E (de)
SG (1) SG157312A1 (de)
SI (1) SI2119448T1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL198545A0 (en) 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof
BR122014027420A2 (pt) 2010-11-03 2019-08-20 Argenx Bvba Anticorpos anti c-met
WO2013064700A2 (en) 2011-11-03 2013-05-10 Argen-X B.V. Chimeric polypeptides and methods of use
GB2504139B (en) 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
WO2013079973A1 (en) * 2011-12-02 2013-06-06 Di Cara Danielle Marie Antibodies against hgf - receptor and uses
CN107002133B (zh) * 2014-11-20 2022-07-05 天主教大学基金会 Met的新型自活化且细胞内的突变体
MX420249B (es) 2016-09-29 2025-02-10 Mitsubishi Tanabe Pharma Corp Agentes de unión monoclonales de cmet, conjugados de fármaco de los mismos y usos de los mismos.
CN113567685B (zh) * 2021-09-26 2022-05-17 瑞博奥(广州)生物科技股份有限公司 基于核酸适配体探针的hgfr识别方法及检测hgfr的试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE155525T1 (de) * 1991-05-10 1997-08-15 Pharmacia & Upjohn Spa Verkürzte formen den hepatozyten wachstumsfaktor (hgf) rezeptors
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
AU2760602A (en) * 2001-03-23 2002-09-26 Agouron Pharmaceuticals, Inc. Catalytic domains of the human hepatocyte growth factor receptor tyrosine kinase, and materials and methods for identification of inhibitors thereof
WO2005058965A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
WO2005108424A1 (en) 2004-05-06 2005-11-17 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor bata chain with met receptor and methods of use
US20060008844A1 (en) * 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
WO2007013603A1 (ja) * 2005-07-28 2007-02-01 Anges Mg, Inc. リンパ管新生促進剤
CA2624535A1 (en) 2005-09-30 2007-04-05 Compugen Ltd. Hepatocyte growth factor receptor splice variants and methods of using same
BRPI0707480A8 (pt) * 2006-02-06 2022-11-08 Vertical Bio Ag Usos de um anticorpo monoclonal, um fragmento e/ou anticorpo geneticamente engenheirado ou humanizado, de uma seqüência de nucleotídeos e de um vetor, produto, e, método para triar compostos
IL198545A0 (en) 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof

Also Published As

Publication number Publication date
SG157312A1 (en) 2009-12-29
CA2665958C (en) 2014-01-07
EP2119448B1 (de) 2011-06-22
US9310377B2 (en) 2016-04-12
IL198545A0 (en) 2011-07-31
SI2119448T1 (sl) 2012-02-29
US20120115219A1 (en) 2012-05-10
ATE513556T1 (de) 2011-07-15
JP2009291191A (ja) 2009-12-17
DK2119448T3 (da) 2011-09-26
BRPI0901502A2 (pt) 2010-01-26
MX2009005049A (es) 2009-12-18
EP2119448A1 (de) 2009-11-18
CA2665958A1 (en) 2009-11-14
US20120108789A1 (en) 2012-05-03
CY1111853T1 (el) 2015-11-04
PL2119448T3 (pl) 2011-11-30
AU2009201893A1 (en) 2009-12-03
PT2119448E (pt) 2011-09-27
KR20090118846A (ko) 2009-11-18
US8404453B2 (en) 2013-03-26
EA017863B1 (ru) 2013-03-29
US20130183690A1 (en) 2013-07-18
JP5623027B2 (ja) 2014-11-12
US9121854B2 (en) 2015-09-01
KR101509263B1 (ko) 2015-04-06
ES2368603T3 (es) 2011-11-18
EA200900537A1 (ru) 2009-12-30
US20090298079A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
Croset et al. miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis–associated genes
Li et al. RUNX2 promotes breast cancer bone metastasis by increasing integrin α5-mediated colonization
Njah et al. A role of agrin in maintaining the stability of vascular endothelial growth factor receptor-2 during tumor angiogenesis
Yamaguchi et al. An anti-interferon activity shared by paramyxovirus C proteins: inhibition of Toll-like receptor 7/9-dependent alpha interferon induction
Ippolito et al. Lactate supports cell-autonomous ECM production to sustain metastatic behavior in prostate cancer
Ma et al. LncRNA MALAT1 knockdown inhibits cell migration and invasion by suppressing autophagy through miR-384/GOLM1 axis in glioma.
JP2009291191A5 (de)
Amarouch et al. Biochemical, single-channel, whole-cell patch clamp, and pharmacological analyses of endogenous TRPM4 channels in HEK293 cells
Gao Biology of Vascular Smooth Muscle
WO2011056975A4 (en) Genetically encoded calcium indicators and methods of use
EP4127172A2 (de) Verfahren und zusammensetzungen zur wiederherstellung des stmn2-spiegels
Nassar et al. Non-caveolar caveolin-1 expression in prostate cancer cells promotes lymphangiogenesis
Phelps et al. Registered report: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs
Wang et al. FERM-containing protein FRMD5 is a p120-catenin interacting protein that regulates tumor progression
EP2521555A4 (de) Verfahren und zusammensetzungen zur erhöhung der sensitivität gegenüber tyrosinkinasehemmern
Wang et al. CircNDC80 promotes glioblastoma multiforme tumorigenesis via the miR-139-5p/ECE1 pathway
Matsushima et al. V843I, a lung cancer predisposing EGFR mutation, is responsible for resistance to EGFR tyrosine kinase inhibitors
Shirasaka et al. Interspecies comparison of the functional characteristics of plasma membrane monoamine transporter (PMAT) between human, rat and mouse
Park et al. High expression of large-conductance Ca2+-activated K+ channel in the CD133+ subpopulation of SH-SY5Y neuroblastoma cells
Sadej et al. Tenascin C interacts with ecto-5′-nucleotidase (eN) and regulates adenosine generation in cancer cells
ATE545033T1 (de) Diagnostische verfahren für hiv-infektion
Sato et al. The β3-adrenoceptor agonist 4-[[(Hexylamino) carbonyl] amino]-N-[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy) propyl] amino] ethyl]-phenyl]-benzenesulfonamide (L755507) and antagonist (S)-N-[4-[2-[[3-[3-(acetamidomethyl) phenoxy]-2-hydroxypropyl] amino]-ethyl] phenyl] benzenesulfonamide (L748337) activate different signaling pathways in Chinese hamster ovary-K1 cells stably expressing the human β3-adrenoceptor
Lang et al. The renin-angiotensin system mediates hyperoxia-induced collagen production in human lung fibroblasts
Klosek et al. CD151 regulates HGF-stimulated morphogenesis of human breast cancer cells
Masoumi-Moghaddam et al. The expression of the Sprouty 1 protein inversely correlates with growth, proliferation, migration and invasion of ovarian cancer cells